国家药监局：2025年共收到创新医疗器械特别审批申请457项 近日，国家药监局发布2025年度创新医疗器械等产品注册审批情况。2025年，国家药监局按照《创新医 疗器械特别审查程序》《医疗器械优先审批程序》继续做好相关产品的审查工作，共收到创新医疗器械 特别审批申请457项，其中104项获准进入创新医疗器械特别审查程序；收到优先申请38项，其中26项获 准优先审批。 国家药监局：2025年475个中药材生产基地通过检查 央视新闻消息显示，记者从2026年全国中药注册管理和质量安全监管工作会上了解到：截至2025年年 底，全国475个中药材生产基地通过延伸检查，种植面积近124万亩，可以提供101种中药材，供给215家 中药生产企业生产275个品种。国家药监局表示，2025年监管部门聚焦中药风险预警，督促中药生产企 业主动强化监测预警，及时采取措施有效控制风险、消除隐患。完善中药说明书安全性信息，印发《已 上市中药变更药品说明书中安全性内容的申报资料撰写要求》。发布5批公告，涉及666个批准文号，完 成相关补充申请21个。 药械审批 上海医药：普瑞巴林胶囊获得菲律宾药品注册证书 2月27日，上海医药(60160 ...

Core Insights - The 2025 China International Service Trade Fair (CIFTIS) commenced in September in Beijing, featuring a forum on "Innovations in Tumor Treatment and New Trends in Drug Development" as a key academic activity [1] - The forum aims to create a high-end communication platform for policy interpretation, results release, industry connection, and international cooperation in the field of tumor prevention and treatment [1][3] Group 1: Forum Objectives and Themes - The forum is centered around the theme "Gathering Global Wisdom to Build a New Future in Cancer Prevention" and focuses on promoting disease prevention research and accelerating the transformation of scientific achievements [3] - The event emphasizes the importance of collaboration among government, industry, academia, and research institutions to enhance tumor prevention and treatment [3][4] Group 2: Scientific and Technological Innovations - Keynote speakers highlighted that technological innovation is crucial for the development of precision medicine in oncology, integrating multi-omics technologies, gene editing, liquid biopsy, and artificial intelligence [4] - The proportion of innovative drugs in development, such as cell therapy and bispecific antibodies, has reached 39% in China, marking a significant shift from generic to innovative drug development [4] Group 3: Challenges and Solutions in Cancer Treatment - Experts discussed the challenges in cancer prevention, including low HPV vaccination rates and insufficient screening coverage, particularly in remote areas and among young women [5][6] - A new model for cervical cancer prevention and control was presented, focusing on a multi-dimensional approach that includes immunology, protein, and gene strategies [6] Group 4: Collaborative Research Initiatives - The forum witnessed the launch of a strategic cooperation agreement for a research project aimed at establishing a standardized system for clinical applications of tumor biotherapy [6] - The project involves multiple institutions and aims to create technical standards and clinical pathways to facilitate the safe and compliant transformation of cutting-edge technologies in the industry [6]

Core Viewpoint - The mid-term performance of Mirxes Holding Company Limited demonstrates its commercial capabilities in the field of early cancer screening [1] Financial Performance - For the first half of 2025, Mirxes achieved revenue of $10.5 million, a 9.4% increase compared to the same period in 2024, driven by a 50% growth in the early detection and precision multi-omics segment, which now accounts for 100% of the company's revenue [4] - The gross profit for this segment reached $7.1 million, reflecting a 102.9% year-on-year increase [4] - The gross margin improved from 49.0% to 67.6%, with gross profit increasing by 51.1% [5][6] - The company reported a significant reduction in losses, down 36.3% to $28.23 million, aided by effective cost management [6] Market Expansion and Strategic Partnerships - Mirxes has engaged in strategic partnerships to enhance its market presence, including a nationwide early screening project in Japan and a memorandum of understanding with PT DIASTIKA BIOTEKINDO in Indonesia [4] - The company’s flagship product, GASTROClear™, has received regulatory approval in Singapore and Thailand, and has been recognized as a "breakthrough medical device" by the FDA in the U.S. [6] Product Development and Future Outlook - The company is advancing its product pipeline, with plans for the CRC-1 colorectal cancer detection product to complete prototype design in the second half of this year and initiate clinical trials in Singapore and China in 2026 [7] - The CEO emphasized the company's commitment to accelerating the global registration process for core products and expanding its product pipeline through a multi-omics technology platform [7]

Core Viewpoint - Shenzhen BGI Genomics Co., Ltd. reported a significant decline in revenue and net profit for the first half of 2025, indicating challenges in the market and operational performance [4][6]. Financial Performance - The company's revenue for the reporting period was approximately 1.63 billion yuan, a decrease of 12.82% compared to the same period last year [4]. - The net profit attributable to shareholders was approximately -30.49 million yuan, representing a drastic decline of 2,610.77% year-on-year [4]. - The basic earnings per share dropped by 67.90% to 0.0139 yuan [4]. - The total assets at the end of the reporting period were approximately 12.49 billion yuan, a slight decrease of 0.45% from the previous year [4]. Business Overview - The company operates as a leader in the global genomics industry, providing comprehensive solutions in gene testing, mass spectrometry, and bioinformatics analysis [5][6]. - BGI Genomics focuses on various health management services, including maternal health, cancer prevention, chronic disease management, and infectious disease control [6][7][8]. - The company has developed a complete maternal health management product system covering all stages from pre-marital to child growth [6][7]. Technological Capabilities - The core technologies include high-throughput sequencing and mass spectrometry, supplemented by single-molecule sequencing and other innovative platforms [7][10]. - The company offers a range of services, including non-invasive prenatal testing, genetic disease screening, and cancer risk assessments [7][8]. Market Position - BGI Genomics has established a marketing service network covering over 100 countries and all provinces in China, positioning itself as a comprehensive service provider in the genomics field [5][6]. - The company aims to enhance the accessibility and efficiency of high-throughput sequencing services through integrated solutions that simplify complex processes [13][12]. Strategic Direction - The company adheres to a strategy of "independent research and development as the main focus, with ecological cooperation as a supplement," emphasizing innovation in precision medicine [12][13]. - BGI Genomics is committed to advancing life science research and improving global health standards through its extensive service offerings [6][12].

Core Viewpoint - The article highlights the advancements in citrus breeding technology that have led to the development of more flavorful and nutritious citrus varieties, transforming the market availability of fresh citrus fruits throughout the year [2][3]. Group 1: Citrus Breeding Technology - Traditional breeding methods involve selecting superior plants from various regions, followed by cross-pollination and extensive evaluation of hybrid offspring to identify desirable traits [2]. - Advanced techniques such as embryo grafting have significantly reduced the time required for hybrid varieties to flower and bear fruit, shortening the breeding cycle to just three to five years [2]. - The development of genomic and phenomic technologies has led to the creation of a citrus "chip," which allows for the identification of over 40,000 core genetic markers from more than 300 representative citrus germplasm resources [2][3]. Group 2: Genetic Editing and Future Prospects - The citrus breeding process has been enhanced by gene editing technologies, specifically the CRISPR-Cas9 system, which allows for precise modifications of genetic material to improve traits such as disease resistance and fruit quality [3][4]. - Theoretically, it is possible to concentrate desirable traits such as high sweetness, juiciness, vitamin content, and high yield into a single variety, although these new varieties are currently limited to laboratory research and not yet available in the market [4]. - With the support of new technologies, the industry anticipates the continuous introduction of tastier and healthier citrus varieties, enhancing consumer experience [5].